Improved Efficiency and Pace of Generating Induced Pluripotent Stem Cells from Human Adult and Fetal Fibroblasts
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
It was reported recently that human fibroblasts can be reprogrammed into a pluripotent state that resembles that of human embryonic stem (hES) cells. This was achieved by ectopic expression of four genes followed by culture on mouse embryonic fibroblast (MEF) feeders under a condition favoring hES cell growth. However, the efficiency of generating human induced pluripotent stem (iPS) cells is low, especially for postnatal human fibroblasts. We started supplementing with an additional gene or bioactive molecules to increase the efficiency of generating iPS cells from human adult as well as fetal fibroblasts. We report here that adding SV40 large T antigen (T) to either set of the four reprogramming genes previously used enhanced the efficiency by 23–70-fold from both human adult and fetal fibroblasts. Discernible hES-like colonies also emerged 1–2 weeks earlier if T was added. With the improved efficiency, we succeeded in replacing MEFs with immortalized human feeder cells that we previously established for optimal hES cell growth. We further characterized individually picked hES-like colonies after expansion (up to 24 passages). The majority of them expressed various undifferentiated hES markers. Some but not all the hES-like clones can be induced to differentiate into the derivatives of the three embryonic germ layers in both teratoma formation and embryoid body (EB) formation assays. These pluripotent clones also differentiated into trophoblasts after EB formation or bone morphogenetic protein 4 induction as classic hES cells. Using this improved approach, we also generated hES-like cells from homozygous fibroblasts containing the sickle cell anemia mutation Hemoglobin Sickle. Disclosure of potential conflicts of interest is found at the end of this article.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More studies are working on enhancing the iPSC reprogramming efficiency, such as by adding SV40 large T antigen (T) by 23–70-fold from human fibroblasts [104].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [104]
In the citing paper
“Suppression of p53 by viral protein or siRNA facilitated reprograming of iPS [70, 71].”
From Ultraviolet Radiation‐Induced Skin Aging: The Role of DNA Damage and Oxidative Stress in Epidermal Stem Cell Damage Mediated Skin Aging (2016) · cites this paper as [71]
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts
Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., & Yamanaka, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1374 · Cited by 2,380
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041
Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells
Draper, J. S., Smith, K., Gokhale, P., Moore, H. D., Maltby, E., Johnson, J., Meisner, L., Zwaka, T. P., Thomson, J. A., & Andrews, P. W. (2004) · Nature Biotechnology · doi:10.1038/nbt922 · Cited by 1,021
c-Myc Is Dispensable for Direct Reprogramming of Mouse Fibroblasts
Wernig, M., Meissner, A., Cassady, J. P., & Jaenisch, R. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.12.001 · Cited by 628
Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation
Ahuja, D., Sáenz-Robles, M. T., & Pipas, J. M. (2005) · Oncogene · doi:10.1038/sj.onc.1209046 · Cited by 557
Cited by
Items 201–291 of 291
Stem Cells in Genetic Myelin Disorders
Kemp, K. C., Mallam, E., Scolding, N. J., & Wilkins, A. (2010) · Regenerative Medicine · doi:10.2217/rme.10.10 · Cited by 8
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Chigurupati, S., Felemban, S. G., Alsubaiyel, A. M., Iqbal, M. S., Bhatia, S., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10390-4 · Cited by 6
Modeling of Gene Therapy for Regenerative Cells Using Intelligent Agents
Adly, A. S., Aboutabl, A. E., & Ibrahim, M. S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7046-6_32 · Cited by 6
“This concept is new compared to the traditional medicine [4–6].”
ResultSecardin, L., Limia, C. E. G., Benedito, S. D. S., Lordier, L., El-Khoury, M., Marty, C., Ianotto, J., Raslová, H., Constantinescu, S. N., Bonamino, M., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000593 · Cited by 6
Papapetrou, E. P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_9 · Cited by 7
Insights into Repeated Renal Injury Using RNA-Seq with Two New RPTEC Cell Lines
Merrick, B. A., Martin, N. P., Brooks, A. M., Foley, J. F., Dunlap, P. E., Ramaiahgari, S., Fannin, R. D., & Gerrish, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814228 · Cited by 5
“The Ef1a_Large T-antigen Puro lentivirus was a gift from Linzhao Cheng [100] via Addgene (Watertown, MA, USA; Cat No. 18922) that contained a puromycin selection marker.”
MethodiPSC-Derived Cardiomyocytes as a Disease Model to Understand the Biology of Congenital Heart Defects
Pushpan, C. K., & Kumar, S. R. (2024) · Cells · doi:10.3390/cells13171430 · Cited by 6
“Similarly, increased efficiency in reprogramming was observed with SV40 LT(T) when NANOG, KLF4 [10], LIN28, or MYC was omitted [11].”
BackgroundProgress and bottleneck in induced pluripotency
Zhang, Z., & Xu, Y. (2012) · Cell Regeneration · doi:10.1186/2045-9769-1-5 · Cited by 5
Liang, C., Xu, Y., Zheng, D., Sun, X., Xu, Q., & Duan, D. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.05.002 · Cited by 5
Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave
Sharp, B., Rallabandi, R., & Devaux, P. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00599-x · Cited by 5
“Finally, integration-deficient LV vectors were developed [93–95], but reprogramming of fetal and adult human fibroblasts led to at least a 50-fold loss in efficiency and a delay in iPSC emergence [94].”
MethodSandoval, A. G. W., Maden, M., Bates, L. E., & Silva, J. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.18034.1 · Cited by 4
Induced pluripotent stem cell (iPS) technology: promises and challenges
Esteban, M. A., Gan, Y., Qin, D., & Pei, D. (2009) · Chinese Science Bulletin · doi:10.1007/s11434-009-0014-9 · Cited by 5
[Induction and characterization of induced pluripotent stem (iPS) cells: a review].
Cheng, D., Lei, L., Lu, Z., Li, Z., & Wang, H. (2010) · PubMed · Cited by 4
Ikeda, K., Kusaba, T., Tomita, A., Uehara-Watanabe, N., Ida, T., Kitani, T., YAMASHITA, N., Uehara, M., Matoba, S., Yamada, T., et al. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000509419 · Cited by 4
Li, R., Nan, G., Wang, D., Gao, C., Yang, J., He, T., & Zhang, Z.-L. (2021) · The International Journal of Developmental Biology · doi:10.1387/ijdb.210062zz · Cited by 4
Application of Human Stem Cells to Model Genetic Sensorineural Hearing Loss and Meniere Disease
Lamolda, M., Frejo, L., Gallego‐Martinez, A., & Lopez-Escamez, J. A. (2023) · Cells · doi:10.3390/cells12070988 · Cited by 5
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics
Mehra, V., Chhetri, J. B., Ali, S., & Roddie, C. (2023) · Biology · doi:10.3390/biology12111419 · Cited by 6
“…transduction of these cells with SV40 large T antigen (the function of which is to disable retinoblastoma (Rb) and p53 tumour suppressor pathways towards enhanced proliferation [61]) or short hairpin RNA (shRNA) against p53 [62] alongside the OKSM factors [32] can improve reprogramming efficiency.”
BackgroundSong, B., Fu, H., Jianwei, L. I. U., Ren, K., Weir, M. D., Schneider, A., Wang, P., Song, Y., Zhao, L., & Xu, H. (2021) · Dental Materials Journal · doi:10.4012/dmj.2019-263 · Cited by 4
Lyde, R. B., Poncz, M., & Lambert, M. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_94 · Cited by 6
Generation of induced pluripotent stem cells from neonatal mouse cochlear cells
Du, D., & Lou, X. (2014) · Differentiation · doi:10.1016/j.diff.2014.02.004 · Cited by 4
Generation and application of human iPS cells
Cui, C., Rao, L., Cheng, L., & Xiao, L. (2009) · Chinese Science Bulletin · doi:10.1007/s11434-008-0579-8 · Cited by 4
Self-citationInduced Pluripotent Stem Cells(iPS Cells):Current Status and Future Prospect*
Shen, H.-F., Yao, Z.-F., Xiao, G., Jia, J.-S., Xiao, D., & Yao, K. (2009) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2008.00794 · Cited by 7
OZAWA, A., Akasaka, E., Watanabe, S., YOSHIDA, M., Miyoshi, K., & Sato, M. (2010) · Journal of Reproduction and Development · doi:10.1262/jrd.09-190a · Cited by 4
Integration-Free Reprogramming of Lamina Propria Progenitor Cells
Howard-Jones, R. A., Cheung, O. K. Y., Glen, A., Allen, N. D., & Stephens, P. (2016) · Journal of Dental Research · doi:10.1177/0022034516637579 · Cited by 3
“…to differentiation conditions, differentiated EBs positively expressed early markers of mesoderm (BRACHYURY), endoderm (α-1FETOPROTEIN), and ectoderm (βIII-TUBULIN), consistent with previous reports for other iPSCs (Aasen et al. 2008; Maherali et al. 2008; Mali et al. 2008; Lin et al. 2009).”
BackgroundResultSelectable Markers for Gene Therapy
Gottesman, M. M., Licht, T., Kimchi‐Sarfaty, C., Zhou, Y., Lee, C. G. L., Shoshani, T., Hafkemeyer, P., Hrycyna, C. A., & Pastan, I. (2000) · CRC Press eBooks · doi:10.1201/9781420002126-28 · Cited by 3
Pittenger, M. F., & Kerr, C. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-420145-3.00002-x · Cited by 6
Weiand, M., Ballmaier, P., Niemietz, C., Schmidt, H., & Zibert, A. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101308 · Cited by 2
“was shown to enhance iPSC formation of human fibroblasts when co-expressed with canonical reprogramming factors [25].”
BackgroundLentiviral vectors as the delivery vehicles for transduction into iPSCs
Kantor, B., & Chiba‐Falek, O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85766-6.00005-x · Cited by 7
Tatwavedi, D., Pellagatti, A., & Boultwood, J. (2023) · Advances in Biological Regulation · doi:10.1016/j.jbior.2023.100993 · Cited by 3
Recent Advances in Stem Cell Research
Kulshreshtha, S., & Bhatnagar, P. (2013) · Springer eBooks · doi:10.1007/978-81-322-1554-7_9 · Cited by 2
Chaudhury, H., Goldie, L. C., & Hirschi, K. (2011) · Genes & cancer · doi:10.1177/1947601911432335 · Cited by 2
Dang, V. L., Spivak, J. L., Moliterno, A. R., Ye, L. C. Z., Zhan, H., Mali, P., Dowey, S. N., Williams, D. M., & Jang, Y. (2009) · Cited by 2
Self-citationTransformation to Inducible Pluripotent Stem Cells
Kodo, K., Ong, S., & Wu, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801888-0.00020-5 · Cited by 3
Ferreira, A. F., Ferreira, F. U., da Costa, P. N. M., Catelli, L. F., de Macedo, M. D. C. F., dos Santos, T. P. M., Leopoldino, A. M., Picanço‐Castro, V., Kashima, S. H., & Covas, D. T. (2019) · Haemophilia · doi:10.1111/hae.13716 · Cited by 2
Omics in Stem Cell Therapy: The Road Ahead
Byun, K., Jeong, G., Collingwood, T. N., & Lee, B. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-940-2_13 · Cited by 2
Yildirimer, L., & Seifalian, A. M. (2015) · Wiley eBooks · doi:10.1002/9781118655412.ch7 · Cited by 2
Aguilera, C., Wong, Y. S., Echeverry, D., Veraguas, D., & Cartes, D. A. (2025) · Annals of Animal Science · doi:10.2478/aoas-2025-0073 · Cited by 1
“Fibroblasts are commonly used in iPSC technology, serving as the benchmark for reprogramming efficiency and differenti - ation potential against which new methods are evaluated (Mali et al., 2008; Park et al., 2008; Raab et al., 2014).”
InfluentialDisease-associated iPS cell lines representing hematological and immunological disorders
Saito, M. K., & Niwa, A. (2012) · Inflammation and Regeneration · doi:10.2492/inflammregen.32.171 · Cited by 1
El inicio de la vida de un nuevo ser humano desde la perspectiva científica biológica
Alcántara, M. S., & Patricio Ventura-Junca, T. (2009) · ARS MEDICA Revista de Ciencias Médicas · doi:10.11565/arsmed.v38i1.86 · Cited by 1
Induced Pluripotent Stem Cells
Takahashi, K., & Yamanaka, S. (2010) · Springer eBooks · doi:10.1007/978-90-481-9075-1_8 · Cited by 1
Induced Pluripotent Stem Cells
Okita, K., Takahashi, K., & Yamanaka, S. (2013) · Springer eBooks · doi:10.1007/978-94-007-5690-8_8 · Cited by 2
Saito, M. K., & Niwa, A. (2016) · Springer eBooks · doi:10.1007/978-4-431-55966-5_6 · Cited by 1
The Use and Promise of Stem Cells in Drug Discovery
Glicksman, M. A., Lam, K., Sittamplalam, G., & Webb, M. L. (2010) · Cited by 1
Ghoneim, M. A., Agina, H. A., El-Baz, M. A., Emarah, N. M., & Khater, S. M. (2016) · Egyptian Journal of Pathology · doi:10.1097/01.xej.0000484379.67282.f8 · Cited by 1
“Recent demonstrations that human ESC-like-induced pluripotent stem cells can be generated from adult human somatic cells by enforced expression of defined transcription factors have raised great hope (Mali et al., 2008).”
BackgroundIntroduction to Stem Cell Therapy and Its Application in Vascular Diseases
Lopes, L. L. N. M., Navarro, T. P., & Dardik, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-56954-9_1 · Cited by 1
How induced pluripotent stem cells changed the research status of polycystic ovary syndrome
Yu, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85765-9.00009-6 · Cited by 1
Yıldırım, S. (2011) · SpringerBriefs in stem cells · doi:10.1007/978-1-4614-2206-8_5 · Cited by 1
Alternative Embryonic Stem Cell Sources
Šarić, T., Mehrjardi, N. Z., & Hescheler, J. (2009) · Springer eBooks · doi:10.1007/978-90-481-3040-5_6 · Cited by 3
The Progress of Induced Pluripotent Stem Cells (iPSCs) for Research and Applications
Fu, Y., Zhou, X., Feng-qing, X. U., & Qian, Q. (2011) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2010.00333 · Cited by 2
Células-tronco pluripotentes induzidas para o estudo e tratamento da anemia falciforme
Reis, L. C. J. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2017.tde-03072017-102445 · Cited by 1
Cells and Vascular Tissue Engineering
Kirton, J. P., Tsai, T.-N., & Xu, Q. (2010) · Springer eBooks · doi:10.1007/978-3-642-11865-4_12 · Cited by 1
“Addition groups, including our own, have now successfully generated human iPS cells confirming this as a reproducible reprogramming technique [166–169].”
BackgroundNew Techniques in the Generation of Induced Pluripotent Stem Cells
Raymond, C. B., Ellen, L., & Peter, J. (2011) · InTech eBooks · doi:10.5772/25208
“Subsequent improvements have been made by using lentiviral vectors to deliver SV40T, UTF1 or p53 shRNA to supplement the reprogramming cocktails, resulting in a 70-100 fold increase in reprogramming efficiency (Mali et al., 2008; Zhao et al., 2008).”
BackgroundMethodInfluentialAdvances in Pluripotent and Adult Stem Cells for Eye Research
Peh, G. S. L., & Wong, R. C. B. (2014) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-0787-8_5
Bioengineered cardiogenicity through nuclear reprogramming: an IPS platform for heart regeneration
Martinez‐Fernandez, A. (2010) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/781
Application of Induced Pluripotent Stem Cells in Rheumatology
Jung, S. M., & Ju, J. H. (2013) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2013.20.5.286
Zhu, X., Ruan, G., Chen, Q., Pang, R., Cai, X.-M., Li, Z., Chen, C.-Z., Lei, L., Wang, Q., He, J., et al. (2012) · CYTOLOGIA · doi:10.1508/cytologia.77.251
“In contrast, the existing strategies using defined factors are inefficient and generation of iPS cells are usually generated from millions of starting cells (Mali et al. 2008, Park et al. 2008, Takahashi et al. 2007).”
BackgroundJambi, M. M., Ye, B., Gollob, M. H., & Davis, D. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.178
“Reprogramming efficiency of human iPSCs generation by lentiviral system was enhanced up to 70 fold when Oct4, Sox2, Klf4 and c-Myc were combined with the SV40 large T antigen under the control of the EF1a promoter [191].”
MethodDERIVATION AND THERAPEUTIC POTENTIALS OF INDUCED PLURIPOTENT STEM CELLS
YANG, L., Lau, M.-S., & Ng, H. (2009) · Gene Therapy and Regulation · doi:10.1142/s1568558609000138
Developmental Maturation within the Hematopoietic System
Arora, N. (2014) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Cell reprogramming for the creation of patient-specific pluripotent stem cells by defined factors
Yin, H., Wang, H., Cao, H., Zhang, Y., Tao, Y., & Zhang, X. (2009) · Frontiers of Agriculture in China · doi:10.1007/s11703-009-0028-8
“In addition, adding SV40 large T antigen (T) to either set of the previously used four reprogramming genes (Oct3/4, Sox2, Klf4 and c-Myc or Oct3/4, Sox2, and Nanog and Lin28) can enhance the efficiency by 23–70 folds from both human adult and fetal fibroblasts (Mali et al., 2008).”
BackgroundMethodINDUCED PLURIPOTENT STEM CELLS A BRIEF REVIEW
Atkinson, S. P., & Armstrong, L. (2009) · Serbian Journal of Experimental and Clinical Research
Mao, B., Lu, X., Huang, S.-K., Yu, J., Lai, M., Tsuji, K., Nakahata, T., & Ma, F. (2015) · SpringerBriefs in stem cells · doi:10.1007/978-94-017-7312-6_2
“Several reports have referred to the successful establishment of hiPSC lines derived from patients with erythrocytes-associated diseases [12–17].”
Background成德, Lei, L., 卢智娟, 李珍, & 王华岩 (2010) · 生物工程学报
Factors affecting the formation, stability, and expression of unintegrated lentiviral vector genomes
Bayer, M. (2010) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/j9mp-1c47
Avances en el desarrollo de la terapia celular para las distrofias musculares
Mondragón-González, R., & Vega, B. C. (2016) · Investigación en Discapacidad
The genetic safety of induced pluripotent stem (iPS) cells
Chen, Q., & Shi, Q. (2012) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2012.00260
Zou, J., Mali, P., Huang, X., Dowey, S. N., & Cheng, L. (2014)
Self-citationPatient-Derived Induced Pluripotent Stem Cells to Target Kidney Disease
Barnes, F. J., & Ricardo, S. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800102-8.00036-9
Basic Research and Clinical Application of Induced Pluripotent Stem Cells
Konuma, N. (2016) · Journal of Nihon University Medical Association · doi:10.4264/numa.75.2_56
Reprogramming of Somatic Cells: Generation of iPS from Adult Cells
Enseñat‐Waser, R. (2009) · Reproductive medicine and assisted reproductive techniques series · doi:10.3109/9780203092910.019
Evaluation of the Production Methods of Induced Pluripotent Stem Cells: A Short Review
Sheykhhasan, M., & Ghiasi, M. (2016) · Journal of Rafsanjan University of Medical Sciences
STEM CELL AND HYPOXIA-BASED APPROACHES TO ENGINEERING BLOOD VESSELS
Kusuma, S. (2014)
1 Human-Induced Pluripotent Stem Cells: Derivation
Rajamani, U., Lenaeus, L., Ornelas, L., & Sareen, D. (2017) · CRC Press eBooks · doi:10.1201/9781315402185-2
Potential application of alternative oxidase (AOX) in neurodegenerative diseases
Zhuang, Y. (2018) · Helda - University of Helsinki Institutional Repository
In Vivo Cell Conversion as a New Cell Therapy
Li, H., Zhang, L., Chen, Y., Wu, Z., Lei, Z., & Chen, G. (2019) · Current human cell research and applications · doi:10.1007/978-981-13-3672-0_10
Self-citationExosomes from embryonic stem cells as a prophylactic vaccine against lung cancer.
Meng, S. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3373
Alhomoudi, A. I. (2020) · Human Biology
Naked mole rat iPSCs and their noncanonical features: a novel tool for aging research
Lee, S., Mikhalchenko, A. E., & Gladyshev, V. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822228-7.00004-7
Cyranoski, D., & Baker, M. (2008) · Nature reports. Stem cells · doi:10.1038/stemcells.2008.93
Yu, J. (2011) · Wiley eBooks · doi:10.1002/9781118147177.ch4
Zhang, Z., Gao, Y., Gordon, A., Wang, Z. Z., Qian, Z., & Wu, W. (2012) · PLoS ONE · doi:10.1371/annotation/2a5e8c51-2ad9-47c7-a4dd-9c9616bab32a
Reprogramming of Somatic Cells: Generation of iPS from Adult Cells
Enseñat‐Waser, R. (2009) · Reproductive medicine and assisted reproductive techniques series · doi:10.3109/9781841847290.019
Induced pluripotent stem cells
Hotta, A., & Yamanaka, S. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997839.004 · Cited by 1
Toward Regeneration of Retinal Function Using Pluripotent Stem Cells
Osakada, F., & Takahashi, M. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-225-0_13
Secardin, L. (2016) · theses.fr (ABES) · doi:10.70675/b0dd9309z619cz4fa7zabe8zdf2c344930b5
Lin, X., & Bui, T. V. A. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102815
Molinari, A., Lucca, C., Vogiatzis, S., Moccia, V., Babbucci, M., Peruzza, L., Negrisolo, E., Trevisan, M., Barzon, L., Centelleghe, C., et al. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1931938
Metadata
- Authors
- Mali, P., Ye, Z., Hommond, H. H., Yu, X., Lin, J., Chen, G., Zou, J., & Cheng, L.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Cheng, Linzhao
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-29
- Volume
- 26
- Issue
- 8
- Pages
- 1998-2005
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2061824613
- Cited by
- 291
- References
- 32
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 9 · 2021: 9 · 2020: 9 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 14 · 2015: 19 · 2014: 19 · 2013: 20 · 2012: 30
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl073781-10)
- National Heart, Lung, and Blood Institute (R01 HL-073781)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Keywords
- induced pluripotent stem cells, fibroblast reprogramming, SV40 large T antigen, reprogramming efficiency, human embryonic stem cells, teratoma formation, embryoid body differentiation, trophoblast differentiation, sickle cell disease, stem cell markers
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cell Line, Culture Media, Fibroblasts, Homozygote, Humans, Karyotyping, Mutation, Lentivirus, Transgenes, Pluripotent Stem Cells, Embryo Culture Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.